

ONLINE RESOURCE 3

BENHAMIDA M, BIHOUEE T, VERSTRAETE M, GRAS LE GUEN C, LAUNAY E.

Online Resource 3 Outcomes Pre- and Post HUGO Guideline Implementation

Sub Group Analysis without patients with comorbidities

	2011 n= 102	2013 n= 154	P value
Treatment ^a and test ^b	42/102 (41%)	23/154 (15%)	< 0.001
At least 1 treatment ^a	45/102 (41%)	42/154 (27%)	< 0.001
At least 1 test ^b	89/102 (87%)	47/154 (32%)	< 0.001
CXR	86/102 (84%)	47/154 (31%)	< 0.001
RSV Nasopharyngeal swabs	28/102 (27%)	22/154 (14%)	0.073
Inflammatory Blood test	30/102 (29%)	15/154 (9.7%)	< 0.001
Antibiotic use	38/102 (37%)	22/154 (14%)	< 0.001
Salbutamol use > 1 dose	8/102 (7.8%)	7/154 (4.6%)	0.28
Corticosteroid use	10/102 (9.8%)	5/154 (3.3%)	0.013
Chest Physiotherapy	6/102 (5.9%)	0/154 (0%)	0.009
Nasogastric fluid replacement	15/102 (14%)	56/154 (36%)	< 0.001
I.V. fluid replacement	22/102 (21%)	19/154 (12%)	0.049
Oxygen use	65/102 (65%)	76/154 (49%)	0.01
O2 max. L/min. median (IQR)	0.5 (0.25-1.0)	0.5 (0.25-2.0)	0.54
Oxygen lenght. d. median (IQR)	1.5 (1.0-2.5)	1.5(1.5-3.0)	0.19
LOS in GP unit. d. median (IQR)	2.0 (1.5-3.5)	2.0 (1.5-3.5)	0.37
ICU transfer	7/102 (6.9%)	4/154 (2.6%)	0.23
All-cause 7-day readmission	4/102 (3.9%)	7/154 (4.6%)	0.59

^aTreatment among antibiotics /salbutamol / corticosteroids

^b Test among CXR / blood test / RSV test

CXR. *chest-X-ray*; RSV. *respiratory syncytial virus*; ATB. *antibiotic prescription* ;

IV. *intravenous*; IQR. *interquartile range*